Abstracts - faqs.org

Abstracts

Health

Search abstracts:
Abstracts » Health

Neuroactive antiretroviral drugs do not influence neurocognitive performance in less advanced HIV-infected patients responding to highly active antiretroviral therapy

Article Abstract:

The effect of antiretroviral therapy, including drugs that have good penetration in cerebrospinal fluid (CSF), on neuropsychologic performance is analyzed. It was found that the use of stable highly active antiretroviral therapy including multiple drugs that have good CSF penetration, was not associated with neuropsychologic performance.

Author: Antinori, Andrea, Narciso, Pasquale, Tozzi, Valerio, Balestra, Pietro, Baldini, Francesco, Giancola, Maria Letizia, Lorenzini, Patrizia, Larussa, Dora, Corpolongo, Angela, Bellagamba, Rita
Publisher: Lippincott Williams & Wilkins, WK Health
Publication Name: Journal of Acquired Immune Deficiency Syndromes (1999)
Subject: Health
ISSN: 1525-4135
Year: 2006
Cerebrospinal fluid

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Persistence of neuropsychologic deficits despite long-term highly active antiretroviral therapy in patients with HIV-related neurocognitive impairment

Article Abstract:

The prevalence and predictors of persistent neuro psychologic (NP) deficits despite long-term highly active antiretroviral therapy (HAART) in patients with HIV-related neurocognitive impairment (NCI) are assessed. It is observed that 59 percent of the patients had persistent NP deficits.

Author: Antinori, Andrea, Narciso, Pasquale, Tozzi, Valerio, Balestra, Pietro, Galgani, Simonetta, Corpolongo, Angela, Bellagamba, Rita, Salvatori, Maria Flora, Visco-Comandini, Ubaldo, Vlassi, Chrysoula, Giudianelli, Marinella
Publisher: Lippincott Williams & Wilkins, WK Health
Publication Name: Journal of Acquired Immune Deficiency Syndromes (1999)
Subject: Health
ISSN: 1525-4135
Year: 2007
Psychological aspects, Clinical report

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Safe treatment interruptions in patient with Nadir CD4 counts of more than 350 cells/muL

Article Abstract:

Clinical, immunologic, and virologic performance of patients with nadir CD4 counts of >350 cells/muL upon treatment interruption is evaluated. Results reveal that treatment interruptions in patients with nadir CD4 counts of >350 cells/muL seem safe for at least 48 weeks.

Author: Zala, Carlos, Cahn, Pedro, Krolewiecki, Alejandro J., Vanzulli, Claudia, Perez, Hector, Cassetti, Isabel, Iannella, Maria del Carmen, Belen Bouzas, Maria, Gun, Ana, Valiente, Jose
Publisher: Lippincott Williams & Wilkins, WK Health
Publication Name: Journal of Acquired Immune Deficiency Syndromes (1999)
Subject: Health
ISSN: 1525-4135
Year: 2006
United States, HIV infection, Drug therapy, HIV infections

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Subjects list: Health aspects, Care and treatment, Patient outcomes, HIV patients, Highly active antiretroviral therapy
Similar abstracts:
  • Abstracts: Selection and persistence of viral resistance in HIV-infected children after exposure to single-dose nevirapine
  • Abstracts: Undiagnosed HIV infection and couple HIV discordance among household members of HIV-infected people receiving antiretroviral therapy in Uganda
  • Abstracts: Natural pregnancies in HIV-serodiscordant couples receiving successful antiretroviral therapy. The incidence of, risk factors for, and sequelae of Herpes Zoster among HIV patients in the highly active antiretroviral therapy era
  • Abstracts: Adverse cerebral outcomes after coronary bypass surgery. Effect of atenolol on mortality and cardiovascular morbidity after noncardiac surgery
  • Abstracts: Cardiorespiratory responses to aerobic training by patients with postpoliomyelitis sequelae. Comparison of two methods to detect publication bias in meta-analysis
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.
Some parts © 2025 Advameg, Inc.